NasdaqGS:HSICHealthcare
How Investors May Respond To Henry Schein (HSIC) Strong Q4 Specialty Products-Driven Margin Expansion
In February 2026, Henry Schein reported strong fiscal 2025 fourth-quarter results, with total net sales rising 7.7% year over year and Global Specialty Products sales increasing 14.6%.
This outperformance in higher-margin specialty products highlights the growing importance of these offerings within Henry Schein’s broader healthcare distribution and solutions portfolio.
We’ll now examine how this strong specialty products growth shapes Henry Schein’s investment narrative and its focus on...